{"id":1398,"date":"2026-11-18T12:40:04","date_gmt":"2026-11-18T10:40:04","guid":{"rendered":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/"},"modified":"2026-11-18T12:40:12","modified_gmt":"2026-11-18T10:40:12","slug":"fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/","title":{"rendered":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It confirms that the output of sponsor-distributed software linked to a medicine, such as dosing reminders, injection trackers or symptom logs, is regulated as drug labelling. For EU companies with US products or plans, it changes how digital tools need to be built, reviewed and maintained.<\/strong><\/p>\n\n<h2>What PDURS is<\/h2>\n<p>PDURS is software disseminated by or on behalf of a drug sponsor that produces end-user output related to the sponsor&#8217;s medicine. &#8220;On behalf of&#8221; can include third-party developers working under an agreement with the sponsor. FDA focuses on the <strong>end-user output<\/strong>: the screens, messages and sounds the user experiences. That output is treated either as part of the FDA-required labelling or as promotional labelling. Software output that is not specific to the sponsor&#8217;s drug generally falls outside PDURS and may instead fall under medical device rules.<\/p>\n\n<h2>Prescribing information or promotional labelling?<\/h2>\n<ul>\n<li><strong>Software essential to safe and effective use<\/strong>, or supported by adequate and well-controlled evidence of a meaningful clinical benefit, can be described in the prescribing information. Device-connected software typically appears in the How Supplied\/Storage and Handling section, and evidence of clinical benefit typically appears in Clinical Studies.<\/li>\n<li><strong>All other PDURS output<\/strong> is generally promotional labelling, whether or not the software connects to a device.<\/li>\n<li>Where software is not necessary for safe and effective use, FDA recommends that the prescribing information says so.<\/li>\n<\/ul>\n\n<h2>Submission and maintenance<\/h2>\n<ul>\n<li>Promotional PDURS output must be submitted on Form FDA 2253 at initial dissemination, and again when the output is revised.<\/li>\n<li>The draft&#8217;s exemption for output already reviewed by FDA&#8217;s device centre has been removed.<\/li>\n<li>Software updates that do not change previously submitted output, such as certain security patches, do not require a new submission, but sponsors must assess each change.<\/li>\n<li>Sponsors can request advisory comments before dissemination.<\/li>\n<li>Device-related submissions, where the software is also a device, are still required separately.<\/li>\n<\/ul>\n\n<h2>The EU contrast<\/h2>\n<p>There is no equivalent EU framework that treats app output as part of the product information. In the EU, a companion app is assessed under the Medical Device Regulation if it has a medical purpose, while sponsor communications fall under the advertising rules of Directive 2001\/83\/EC and national provisions, including EOF&#8217;s rules in Greece. Companies running one app in both regions need to manage two different compliance models.<\/p>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA helps companies assess the regulatory status of digital tools linked to their medicines, including medical device qualification under the MDR, advertising compliance in Greece and the EU, and the governance needed to keep software output aligned with approved product information.<\/p>\n<p><a href=\"\/el\/contact\/\">Talk to PQRA about your companion software<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It confirms that the output of sponsor-distributed software linked to a medicine, such as dosing reminders, injection trackers or symptom logs, is regulated as drug labelling. For EU companies with US [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1399,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA\" \/>\n<meta property=\"og:description\" content=\"In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It confirms that the output of sponsor-distributed software linked to a medicine, such as dosing reminders, injection trackers or symptom logs, is regulated as drug labelling. For EU companies with US [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T10:40:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-18T10:40:12+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling\",\"datePublished\":\"2026-11-18T10:40:04+00:00\",\"dateModified\":\"2026-11-18T10:40:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/\"},\"wordCount\":466,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-fda-pdurs.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/\",\"name\":\"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-fda-pdurs.png\",\"datePublished\":\"2026-11-18T10:40:04+00:00\",\"dateModified\":\"2026-11-18T10:40:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-fda-pdurs.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-fda-pdurs.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/","og_locale":"el_GR","og_type":"article","og_title":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA","og_description":"In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It confirms that the output of sponsor-distributed software linked to a medicine, such as dosing reminders, injection trackers or symptom logs, is regulated as drug labelling. For EU companies with US [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/","og_site_name":"PQRA","article_published_time":"2026-11-18T10:40:04+00:00","article_modified_time":"2026-11-18T10:40:12+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling","datePublished":"2026-11-18T10:40:04+00:00","dateModified":"2026-11-18T10:40:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/"},"wordCount":466,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-fda-pdurs.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/","url":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/","name":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-fda-pdurs.png","datePublished":"2026-11-18T10:40:04+00:00","dateModified":"2026-11-18T10:40:12+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-fda-pdurs.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-fda-pdurs.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/fdas-final-pdurs-guidance-when-a-companion-app-becomes-drug-labelling\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"FDA\u2019s Final PDURS Guidance: When a Companion App Becomes Drug Labelling"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1398"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1398\/revisions"}],"predecessor-version":[{"id":1400,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1398\/revisions\/1400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1399"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}